Text Size

Real-Time MV/kV Image Guided Radiation Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Stanford University.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT01260909
First received: December 14, 2010
Last updated: March 11, 2011
Last verified: March 2011
History of Changes
  Purpose

In current radiation therapy, imaging (typically, cone beam CT imaging or two orthogonal X-ray projection imaging) is done for patient setup before radiation dose delivery. Dose delivery typically takes 2 to 5 minutes depending on the delivery technique used for treatment. A tumor target may change its position during the dose delivery process. The goal of this project is develop a real-time imaging strategy to monitor the tumor position during dose delivery and evaluate its potential clinical impact.


Condition Intervention
Prostate Cancer
 Device: Real-time kV/MV Prostate Imaging

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Real-Time MV/kV Image Guided Radiation Therapy

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To verify improved tumor targeting accuracy using IMRT (intensity modulated radiation therapy) and VMAT (volumetric modulated radiation therapy) [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 48
Study Start Date: May 2011
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Real-time kV/MV Prostate Imaging Device: Real-time kV/MV Prostate Imaging
The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
Other Names:
  • Image-guided radiation therapy
  • External beam radiotherapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The study population will be drawn from available patient population that will be treated using IMRT/VMAT. The Stanford population of IMRT/VMAT will be taken as roughly representative of prospective IMRT patients and will not be subdivided by any additional characteristics.

Exclusion Criteria:

  • The study population will be drawn from available patient population that will be treated using IMRT/VMAT. The Stanford population of IMRT/VMAT will be taken as roughly representative of prospective IMRT patients and will not be subdivided by any additional characteristics.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01260909

Contacts
Contact: Lei Xing (650) 498-7896 lei@stanford.edu

Locations
United States, California
Stanford University School of Medicine Not yet recruiting
Stanford, California, United States, 94305
Contact: Lei Xing     650-498-7896     lei@stanford.edu    
Contact: Cancer Clinical Trials Office     (650) 498-7061        
Principal Investigator: Lei Xing            
Sub-Investigator: Steven L Hancock            
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Investigators
Principal Investigator: Lei Xing Stanford University
  More Information

No publications provided

Responsible Party: Lei Xing, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT01260909     History of Changes
Other Study ID Numbers: SU-12132010-7282, PROS0038, R21CA153587
Study First Received: December 14, 2010
Last Updated: March 11, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 19, 2013